Navigation Links
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Date:5/7/2009

Study Results Demonstrated Significant Weight Loss in Obese Patients Treated with Qnexa

MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that data from the previously reported 28-week phase 3 EQUATE trial of Qnexa(TM) in obese patients are being presented today at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands. The results, titled "Weight Loss at 6 Months with VI-0521 Treatment," will be presented at the Hot Topic poster session by Donna H. Ryan, M.D., Associate Executive Director for Clinical Research, Pennington Biomedical Research Center in Baton Rouge, LA. The presentation marks the first time these results have been shared with the medical community at a major medical meeting.

The phase 3 EQUATE trial evaluated weight loss achieved with two doses of Qnexa versus that achieved with placebo among 756 patients over 28 weeks. Patients taking full-dose and mid-dose Qnexa achieved an average weight loss of 9.2 percent and 8.5 percent, respectively, as compared to 1.7 percent reported for the placebo group. All results were evaluated using ITT-LOCF, the method of analysis required by the U.S. Food and Drug Administration.

"Obesity has reached epidemic proportions, affecting more than 300 million people worldwide and contributing to increased prevalence of life-threatening illnesses such as hypertension, diabetes, cardiovascular disease and stroke. Patients are in urgent need of new, safe and effective tools to help them achieve the weight loss critical to their health and wellbeing," said Dr. Ryan. "The weight loss seen in patients taking Qnexa, over just 28 weeks, is encouraging for those of us in the medical community treat
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
2. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
7. Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
8. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
9. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Research and Markets has ... Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market ... offering. On the basis of ... has been divided into eight major segments, namely, ... hydromechanical ablation technologies. The light/laser ablation technology segment ...
(Date:9/22/2014)... Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... fiscal 2014 ended July 31, 2014 on Monday, September 29 ... discuss the results at 11:00 AM ET. Participating in the ... Andrew A. Krakauer , President and CEO; Jorgen B. ... Sheldon , Senior Vice President, CFO and Treasurer; and ...
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4
... Ad, " This is Medicare and America at ... WASHINGTON, Dec. 9 The SCOOTER Store today launched a ... and cost savings associated with Medicare,s Power Mobility Benefit, which ... to receive power wheelchairs. , With budget cuts likely in ...
... , ROCKVILLE, Md., Dec. 9 Novavax, Inc. (Nasdaq: ... closed its previously announced public offering of 6,800,000 shares of ... net proceeds from the sale of the shares, after underwriting ... which will be used for preclinical studies and clinical trials ...
Cached Medicine Technology:The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicare's Power Mobility Benefit 2NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2
(Date:9/22/2014)... News) -- Teens and young adults at risk for ... help prevent risky sexual behaviors, according to new recommendations ... year, about 20 million new sexually transmitted infections such ... About half involve people between 15 and 24 years ... new report, published Sept. 22 in Annals of ...
(Date:9/22/2014)... surprising new study pulls back the curtain on one ... in payment and income between physicians who perform operations, ... Contrary to perception, the research indicates, the physician payment ... other procedure-performing doctors. , The new findings counter the ... per minute explains why doctors who perform procedures often ...
(Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , ... for hip bursitis treatment in Manhattan. This treatment is now offered ... bursitis, which is also called trochanteric bursitis, occurs when ... is a fluid-filled sac in the hip, between the ...
(Date:9/22/2014)... By Steven Reinberg ... -- Pediatricians are urging that all children aged 6 months ... The American Academy of Pediatrics updated their influenza vaccine recommendations ... doses of vaccine to build immunity. The AAP also wants ... their kids the nasal spray vaccine instead of the flu ...
(Date:9/22/2014)... patients undergoing breast cancer surgery require additional operations because ... in the initial operation. However, researchers at Brigham and ... developed that will help surgeons better distinguish cancerous breast ... repeat operations. , The study is ... the Proceedings of the National Academy of Sciences ...
Breaking Medicine News(10 mins):Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:The fine line between breast cancer and normal tissues 2
... By Randy Dotinga and Steven Reinberg HealthDay Reporters ... into full swing, a new report Wednesday warns that water pollution ... beach. Last year was one of the worst in two ... Gulf of Mexico oil spill and rainy weather, according to ...
... the most common form of ovarian cancer is characterized by ... changes in the genome itself, said members of The Cancer ... Medicine ( www.bcm.edu ) Human Genome Sequencing Center ( ... tumors. The study was the first to achieve an overview ...
... Chicago --- The 4th edition of the Concise Guide ... Hospital,s psychiatrists, Mina Dulcan, MD, and Mary Beth Lake, ... Dulcan is department head of Child and Adolescent Psychiatry ... School of Medicine. Lake is a child psychiatrist at ...
... Aviv Parkinson,s Disease, brought to public awareness by ... difficult to diagnose. It,s also difficult to accurately estimate ... statistics come from small-scale studies, usually based on information ... exist to track how many people have the disease. ...
... scientists at the University of California, San Francisco has developed ... determining the order in which mutations emerge in them as ... invasive, malignant masses. The work may give doctors ... of early cancers, when they are generally more treatable than ...
... at least 116 million adult Americans experience chronic pain, a ... billion annually, says a new report from the Institute of ... be better managed, added the committee that wrote the report. ... of public and private organizations to create a cultural transformation ...
Cached Medicine News:Health News:Pollution Took Heavy Toll at U.S. Beaches in 2010 2Health News:Pollution Took Heavy Toll at U.S. Beaches in 2010 3Health News:Pollution Took Heavy Toll at U.S. Beaches in 2010 4Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 2Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 3Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 4Health News:Latest guide on child and adolescent psychiatry 2Health News:Getting an accurate read on Parkinson's 2Health News:Getting an accurate read on Parkinson's 3Health News:UCSF-led team decodes evolution of skin and ovarian cancer cells 2Health News:IOM report calls for cultural transformation of attitudes toward pain and its prevention and management 2Health News:IOM report calls for cultural transformation of attitudes toward pain and its prevention and management 3
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: